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The small molecule 4-hydroxy-3-methoxybenzaldehyde (5,6,7,8-tetrahydro[1]benzothieno[2,3-
d]pyrimidin-4-yl)hydrazone (Exo2) stimulates morphological changes at the mammalian Golgi and 
trans-Golgi network that are virtually indistinguishable from those induced by brefeldin A.  Both 10 
brefeldin A and Exo2 protect cells from intoxication by Shiga(-like) toxins by acting on other 
targets that operate at the early endosome, but do so at the cost of high toxicity to target cells.  The 
advantage of Exo2 is that it is much more amenable to chemical modification and here we report a 
range of Exo2 analogues produced by modifying the tetrahydrobenzothienopyrimidine core, the 
vanillin moiety and the hydrazone bond that links these two.  These compounds were examined for 15 
the morphological changes they stimulated at the Golgi stack, the trans Golgi network and the 
transferrin receptor-positive early endosomes and this activity correlated with their inherent 
toxicity towards the protein manufacturing ability of the cell and their protective effect against 
toxin challenge.  We have developed derivatives that can separate organelle morphology, target 
specificity, innate toxicity and toxin protection.  Our results provide unique compounds with low 20 
toxicity and enhanced specificity to unpick the complexity of membrane trafficking networks. 
. 
Introduction  
Membrane and vesicular transport is fundamental to the 
organization and function of all eukaryotic cells.  Newly 25 
synthesised proteins for secretion are transported between the 
intracellular compartments of the endoplasmic reticulum 
(ER), Golgi apparatus and trans-Golgi network (TGN) using a 
defined set of vesicular and tubular intermediates whose 
formation is tightly controlled by a series of regulatory 30 
proteins.  A reverse pathway likewise involves the regulated 
formation of transport intermediates that traffic internalized 
proteins from the plasma membrane via the complex 
endosomal system and on to either lysosomes or, in the 
‘retrograde’ pathway, the TGN, Golgi and ER.1, 2  A cartoon 35 
depicting an overview of the course of membrane transport is 
shown in Figure 1.  Some protein toxins highjack the 
retrograde route to reach the ER and deliver their lethal cargo 
(e.g. the bacterial cholera and Shiga-(like) toxins  
and plant toxin ricin) yet have been invaluable in the 40 
description of the steps and key regulatory proteins that  
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operate in these pathways.3-8  Chemical intervention with 
small molecule inhibitors of trafficking has also played a role 
but these are often pleiotropic in their action and their effects 
are accompanied by high levels of (often unreported) toxicity 55 
(vide infra).  Molecules with more specific activity and low 
inherent toxicity towards treated cells could finesse greater 
detail, understanding and control of trafficking processes.  
 To date, the fungal metabolite brefeldin A (BFA, Fig. 1) is 
the best characterized inhibitor of both secretion and toxin 60 
retrograde transport.9, 10  It promotes the complete disruption 
of the Golgi apparatus and the fusion of Golgi and ER 
compartments.  It also significantly disrupts the structure of 
the TGN, promoting the tubulation and merging of the TGN 
and endosomal compartments.  The structure of BFA and a 65 
cartoon depiction of these effects are shown in the left hand 
lane of Figure 1.  BFA targets at least three guanine 
nucleotide exchange factors (GEFs) that regulate the activity 
of members of the ADP Ribosylation Factor (Arf) family of 
small GTPases.11  These are required for the concentration of 70 
cargo and the formation of coated transport carriers from 
various intracellular compartments such as the TGN, Golgi 
and early endosomes (EE).  Arf1 is a critical trigger of coated 
carriers in the secretory and retrograde transport pathways 
where there are three known Arf1-specific GEFs:  the Golgi-75 
specific GBF1 and the TGN/endosomal BIG1 and BIG2 
proteins.12, 13  BFA inhibits all three by binding at the 
interface between a GDP bound Arf (GDP-Arf) and its GEF, 
stabilising an abortive GDP-Arf/Arf-GEF complex.14  It also 
inhibits activation of Arf315 and Arf416 via their family of 80 
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Arf-GEFs, highlighting the pleiotropic nature of this inhibitor.  
The mechanism of interfacial inhibition, where protein-protein 
interactions are stabilized to give a non-productive complex,17 
as opposed to drug-induced inhibition of productive 
complexes, has been proposed as an attractive way to treat 5 
human disease.18, 19  
Figure1. Cartoon depicting the course of membrane  transport in cells 
and the morphological effects of Brefeldin A and Exo2. 
 Several small molecule inhibitors of membrane transport 
have now been discovered from chemical genetics screens7, 20-10 
27 or by in silico approaches.18  One of these molecules, 4-
hydroxy-3-methoxybenzaldehyde (5,6,7,8-tetrahydro[1]-
benzothieno-[2,3-d]pyrimidin-4-yl)hydrazone28 (Exo2) is 
BFA-like in many respects, halting protein secretion and 
prompting similar morphological changes.  Likewise, Exo2 15 
induces complete disruption of the Golgi apparatus, fusion of 
Golgi and ER compartments29 and significantly disrupts the 
structure of the TGN, but it does not promote the tubulation 
and merging of the TGN and endosomal compartments typical 
of treatment with BFA.30  Thus it appears to interact with a 20 
subset of the GDP-Arf/Arf-GEF targets of BFA.30  The 
structure of Exo2 and a cartoon depiction of the 
morphological changes brought about by Exo2 treatment of 
cells is shown in the right hand lane of Figure 1. 
 Both BFA and Exo2 exhibit a strong protective effect 25 
against intoxication by the Shiga toxins,30, 31 major virulence 
factors produced by the dysentery-causing bacterium Shigella 
dysenteriae32 and by enterohemorrhagic strains of E. coli, 
including the infamous food-poisoning serotype O157:H7.33  
These toxins normally traffic from the cell surface, via EE, 30 
the TGN and the Golgi, to the ER, where the homopentameric 
receptor-binding B chain complex and the cytotoxic A chain 
are separated.  The A chain then retrotranslocates the ER 
membrane to enter the cytosol where it inhibits protein 
synthesis by depurinating a specific adenosine of the 28S 35 
RNA in the large ribosomal subunit.8  Exo2 blocks the 
retrograde trafficking of these toxins at the EE–TGN 
interface.30 
 Due to its modular synthesis,30 we were able to produce a 
range34 of Exo2 analogues in an attempt to enhance these 40 
attributes.  The compounds were individually screened for 
their effect on organelle morphology and function, target 
specificity, innate toxicity and their ability to protect cells 
against an acute challenge of E. coli Shiga-like toxin I 
(SLTx).  We have identified the functional groups that are 45 
critical for the activity of Exo2 and tailored this activity to 
design new molecules with both enhanced target specificity 
and reduced inherent toxicity. 
Results 
Chemistry 50 
Brefeldin A and Exo2 are shown in Figure 1.  To help 
illustrate our approach to a structure activity-relationship 
(SAR) study based on Exo2, we have described Exo2 in terms 
of rings A, B, C and E and the hydrazone linker group D 
(Figure 1).  Initial studies focused on altering the fused 55 
tricyclic pyrimidine core ABC involving modifications to the 
A ring and substitution on the pyrimidine ring C.  The 
hydrazone link D was replaced by amine and triazole 
functionalities.  Finally, the importance and nature of the 
substituents on ring E of the hydrazone was determined. 60 
 The intermediates made on route to generating the 
modifications to the tricyclic thienopyrimidone ring system 
are shown in Scheme 1.  The thienopyrimidones 5-8,16 were 
obtained using a similar synthetic route as described for 
Exo2.30  Using the Gewald reaction,35 commercial ketones 65 
were condensed with ethyl cyanoacetate in the presence of 
sulphur to give the aminothienyl esters 1-4.  Cyclisation of the 
esters in formamide produced the thienopyrimidones 5-8. The 
hydrazine derivatives 9-12 were obtained in two steps from 
the pyrimidones 5-8 using previously published conditions.30  70 
The final step was the condensation of the hydrazines 9-12 
with vanillin to afford Exo2 and compounds 13-15 comprising 
of larger alkyl rings and ring cleaved analogues of Exo2.  In a 
similar manner, cyclisation of 1 in acidic acetonitrile gave the 
methyl pyrimidone 16, conversion to hydrazine 17 and 75 
reaction with vanillin gave 18, a C ring substituted Exo2 
analogue. 
 Attention then turned to the hydrazone linker group D.  
Initially, we examined the simple amino analogue 20 of Exo2 
synthesised by the reaction of chloride 19 with tyramine 80 
(Scheme 2).  Unfortunately, cells treated with 20 showed a 
large reduction in protein synthesis ability (see later) and this 
toxicity lead us to discount any further research in this line of 
analogues.  We have previously published results detailing the 
oxidation and rearrangement of the hydrazone linker of Exo2 85 
derivatives leading to fused 1,2,4-triazolopyrimidines.36  
Although these derivatives showed less inherent toxicity, they 
exhibited no morphological effects, had low solubility and 
little protective ability against STLx challenge.  Concerned 
that the fused pyrimidine triazole ring system presented the E 90 
ring of these Exo2 analogues in an inappropriate orientation 
(see Figure 2), we now synthesised non-fused triazole 
analogues accessible via “click chemistry”.37  Our approach to 
these derivatives is shown in Scheme 3.   Alkyne 21 was 
available via Sonogashira coupling between the chloride 19 95 
and ethynyltrimethylsilane.  Deprotection using TBAF gave 
the alkyne component 22.  The azide partner for the formation 
of a “click”analogue of Exo2 was obtained in two steps from 
4-nitroguaiacol 23 which was reduced to the corresponding  
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 Scheme 1. Synthesis of A and C ring analogues of Exo2 (a) formamide, heat; (b) POCl3, DMF, rt, 18hr, 30-80%; (c) hydrazine monohydrate, MeOH, rt, 
2hr, 60-80%; (d) vanillin, MeOH, 40-90%; (e) cat. conc. HCl, acetonitrile, 85°C, 54%. 
amine 2438 and then converted to the azide 25.39  Benzylic 
azides 26-28 were synthesized from the appropriate 
hydroxybenzyl alcohol,40 and the same methodology was 5 
applied to afford the benzylic azide 29 after reduction of 
vanillin with NaBH4.  Finally the copper(I) catalyzed version 
of the azide-acetylene Huisgen 1,3-dipolar cycloaddition37 
was carried out to afford the 1,2,3-triazole analogues 30-34.   
The regiochemistry of the cyclisations were confirmed by 10 
correlation spectroscopy which showed the expected NOE 
interactions between the triazole CH and the ortho protons of 
ring E. 
Scheme 2. (a) Et3N, iPrOH, 90°C, 18hr, 60% 
 15 
 Attention then turned to alterations on ring E where rapid 
access to a family of compounds to gauge the importance of 
the position and nature of the substituents on ring E was 
available from a library of hydrazone derivatives.  Hydrazones 
35a-r and 35w-z were prepared from condensation of 9 with 20 
commercially available aldehydes (Table 3) and the others 
synthesized via a short route starting from 4-allyloxy-3-  
Figure 2. Possible triazole mimics of the hydrazone link 
hydroxybenzaldehyde 36.41  Using allyl as a protecting 
group42 following a sequence of alkylation to give the ethers 25 
37a-c and then deprotection gave the 3-alkyloxy-4-hydroxy 
substituted aldehydes 38a-c (Scheme 4).  Aldehydes 38a-c 
were finally condensed with 9 to afford the hydrazone  
analogues 35s-v.  The compounds shown in Table 3 probe the 
importance of the substituent(s) and their orientation on ring E 30 
and comprise of an Exo2 isomer (35a), various hydroxy and 
methoxy analogues (35b to 35l ), a random selection of 
substituents (35m to 35r), an investigation of the meta alkoxy 
chain length (35s to 35v) and finally possible hydroxy 
isosteres (35w to 35z). 35 
Biological testing.  
Exo2 treatment of HeLa cells causes the fusion and swelling 
of the endosomes and blocks egress of SLTx from EE to the 
TGN.30  We therefore probed the viability of this retrograde 
trafficking pathway in cells treated with Exo2 and these 40 
derivatives by examining their individual abilities to protect 
these cells from intoxication by SLTx.  HeLa cells were 
treated with a fixed dose (50 ng.ml-1) of SLTx in medium 
containing either vehicle DMSO or 50µM compound diluted 
from DMSO, conditions already established for Exo2,30 after 45 
which protein synthesis ability was determined by measuring 
incorporation of [35S]-methionine into acid-precipitable 
material (PST, Tables 1, 2 and 3).  Results for each compound 
were normalized to coeval controls that measured the protein 
synthesis ability of cells treated with compound alone (PS, 50 
Tables 1, 2, 3 and Charts 1S, 2S, 3S in SI).  These figures are 
shown in the related tables and as a comparison, compound 
efficacy (χ) is quantified as a protective effect calculated as 
the ratio of protein synthesis remaining after treatment with 
compound and SLTx toxin challenge compared to protein 55 
synthesis on treatment with compound alone.  The latter 
reveals the impact of the compound itself on the protein 
synthesis capability of the cells.  For example, although only 
~42% protein synthesis ability remains in cells treated with  
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Scheme 3. Synthesis of 1,4-triazine analogues of Exo2 (a) TBAF, THF, 90%; (b) H2, 10% Pd/C, EtOH, 90%; (c) NaNO2, NaN3, HCl(aq), (d)  PPh3, NaN3, 
DMF / CCl4 (4:1), 43-60%; (e) NaBH4, THF, 66%; (f)  CuSO4.5H2O, sodium ascorbate, EtOH / H2O / THF (1:1:1), 30-60%.
Exo2 alone (PS, Table 1, Chart 1S in SI), ~41% remains in 
cells treated with Exo2 and SLTx (PST, Table 1), so the latter 
cells retain ~95% of their protein synthesis ability following 5 
toxin treatment (χ, Table 1).  Thus Exo2 has high efficacy 
against SLTx challenge.  In contrast, the vehicle DMSO, 
whilst having no effect on protein synthesis ability by itself, 
has a small protective effect against SLTx, with ~39% protein 
synthesis ability remaining after toxin challenge.  The small 10 
protective effect of DMSO has been noted before,43 and has 
been attributed to decreased fluidity of membranes which 
reduces toxin delivery.  
 The morphological changes stimulated by Exo2 are 
believed to be responsible for its protective effect against a 15 
SLTx challenge but also its inherent toxicity.30  Thus, 
protection against incoming toxin might correlate with  
Scheme 4. Synthesis of meta alkoxy, para hydroxy aldehydes (a)
 K2CO3, DMF, R1-Br, rt, 18hr, 51-70%; (b) Pd(OAc)2, PPh3, 
HCOOH, 90°C, 6hr, 25-75% 20 
toxicity of the compound.  It is immediately apparent from the 
numbers in the tables and shown pictorially in Charts 1S, 2S 
and 3S in SI that there is no clear link between the ability to 
protect against SLTx and the innate toxicity of each 
compound, suggesting that more selective inhibitors exist 25 
amongst these derivatives. 
 In parallel, we examined the morphological changes 
stimulated by these compounds.  Fixed cells were stained for 
the TGN marker TGN4644 and the Golgi marker giantin45 
(Figure 1S in SI), and examined by widefield microscopy.  30 
Cells treated with DMSO have a ribbon–like TGN and 
perinuclear Golgi, whilst in cells treated with Exo2 both of 
these structures are widely dispersed, leaving just a few 
remaining punctae.30  An intermediate state between these 
morphologies is exemplified by compound 35l (see Table 3 35 
and Figure 1S in SI) which has a partial disruption of both 
TGN and Golgi structures, with replacement of ribbon-like 
perinuclear structures with numerous punctuate structures.  
Designating a DMSO-like phenotype as ‘D’, an Exo2-like 
phenotype as ‘E’ and an intermediate effect as ‘I’, we 40 
characterised the Exo2 analogues as detailed in the relevant 
Tables.  We also examined the appearance of transferrin 
receptor (TnfR)-positive early endosomes after challenge with 
DMSO, Exo2 and Exo2 analogues, noting in a similar manner 
‘D’ (DMSO-like, normal endosomal appearance), ‘E’ (Exo2-45 
like, swollen endosomes) and an intermediate effect as ‘I’ 
(Table 1, 2 and 3 and Figure 1S in SI).  The endosomal ‘E’ 
phenotype differs from that stimulated by BFA treatment 
which causes endosomal tubulation (Figure 1S in SI).  None 
of the compounds tested generated a BFA phenotype at the 50 
transferrin receptor (TnfR)-positive early endosomes. 
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Table 1. Table 1. Modification of the alkylthienopyrimidine rings ABC  
 
 ZY  
X Golgi TnfR PS PST (χ) 
DMSO - - D D 100 39.3 39.3 
Exo2 
 
H E E 42.1 40.7 96.8 
13 
 
H E E 16.6 16.2 97.6 
14 
 
H E D 9.4 9.2 97.6 
15 
H3C
H3C
 
H D/I D 65.6 42.1 64.1 
18 
 
CH3 I D 41.6 24.4 58.6 
 
TGN and Golgi phenotypes: D, DMSO-like; I, intermediate; E, Exo2-like. 
TnfR+ endosome phenotypes: D, DMSO-like; E, Exo2-like. PS: protein 
synthesis compound only, PST: protein synthesis with toxin challenge. 5 
(χ) protective coefficient (%) 
 
Modification of the alkylthienopyrimidine core ABC 
 
A range of compounds were prepared varying the 10 
alkylthienopyrimidine core of Exo2 and tested for their ability 
to inhibit SLTx transport compared with their inherent 
toxicity and characterised by their effects on the morphologies 
of the TGN/Golgi and endosomes (Table 1 and Chart S1 in 
SI).  Increasing the cycloalkane ring size to seven (13) and 15 
eight carbons (14) retains a similar protective effect (χ) ratio 
but shows a steep increase in toxicity with an accompanying 
erosion of an Exo2 phenotype.  Clipping ring A, analogue 15 
has less inherent toxicity but a reduced protective effect 
against SLTx and again showing reduced morphological 20 
effects.  Substitution on the pyrimidine ring (18) was similarly 
disadvantageous.  These changes on the alkythienopyrimidine 
core were detrimental and highlight the importance of this 
structural region of Exo2 for eliciting both a protective effect 
and phenotypic response.  This suggests that the binding site 25 
cleft of the Exo2 target(s) is relatively restricted and cannot 
easily accommodate the larger cycloheptenyl or cyclooctenyl 
rings of compounds 13 and 14, but also shows a weaker 
interaction with the shorter core of 15.  
Modifications of the hydrazone link D 30 
Exchange of the hydrazone NH-N=CH fragment of Exo2 with 
aminoethyl NH-CH2-CH2 gave compound 20 that exhibited 
very high toxicity drastically reducing protein synthesis 
ability and exhibiting no morphological effects dissuading us 
from further study of this group as a hydrazone replacement.  35 
We have previously reported an alternative modification 
involving the synthesis of a series of fused 1,2,4-triazole Exo2 
derivatives (see Figure 2) obtained by oxidative cyclisation of 
the precursor hydrazones.36  These molecules unfortunately 
did not protect against SLTx challenge.  As the ring fused 40 
triazole skeletons may not present the E ring and its 
substituents in an optimal orientation for substrate binding, we 
synthesised 1,4-substituted triazoles (30-34) via the Huisgen 
1,3-dipolar cycloaddition.37 Although postulated as an amide 
isostere,46 we considered the 1,4-substituted 1,2,3-triazole 45 
could also retain the appropriate geometry and suitable atoms 
to chemically mimic the hydrazone bond (see Figure 2).  
These triazole compounds consisted of both the analogous 
Exo2 derivative (30) and the benzyl analogues (31-34) 
(Scheme 4) that may allow extra degrees of freedom in 50 
presenting the key hydroxyl substituents (vida infra).  
Although all such modifications to Exo2 gave rise to 
molecules with low toxicity (Table 2, Chart 2S in SI), in all 
cases, exchange of the hydrazone bond for a 1,4-substituted 
triazole (30-34) was deleterious, with marked loss of ability to 55 
stimulate visible morphological changes at the TGN/Golgi  
Table 2. Modification of the hydrazone group D 
 R1 Golgi TnfR PS PST  (χ) 
DMSO - D D 100 39.3 39.3 
Exo2 NHN
OH
OCH3
 
E E 42.1 40.7 96.8 
20 HN
OH
 
D D 9.2 4.8 51.5 
30 N
N OH
OCH3
N
 
I D 73.1 17.8 24.3 
31 N
N
OH
OCH3
N
 
n.d. n.d. 63.1 24.2 38.4 
32 N
NN
HO
 
D D 75.1 47.4 61.5 
33 N
N
OH
N
 
D D 87.7 53.9 61.5 
34 N
NN
OH
 
D D 80.4 35.1 43.7 
 
 
TGN and Golgi phenotypes: D, DMSO-like;  I, intermediate;  E, Exo2-
like. TnfR+ endosome phenotypes: D, DMSO-like;  E, Exo2-like;  n.d., 60 
not determined. PS: protein synthesis compound only, PST: protein 
synthesis with toxin challenge. (χ) protective coefficient (%) 
N
NZY
S
HN N
OH
OMe
X
N
N
S
R1
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Table 3. Hydrazone formation and substituents on ring E ring 
 
 
No Ar TGN Golgi TnfR  PS PST (χ) No Ar 
TGN 
Golgi TnfR  PS PST (χ) 
DMSO  D D 100 39.3 39.3 35m 
 
I E 58.5 36.7 62.6 
Exo2 
OH
OMe  
E E 42.1 40.7 96.8 35n 
F
 
I D 60.9 38.4 63.0 
35a 
OMe
OH  
I I 41.2 33.6 81.6 35o 
F  
I D 57.7 36.6 63.4 
35b 
OH
OH  
E E 49.5 42.7 86.1 35p N
 
I D 77.0 34.1 44.3 
35c 
OHHO
 
I/E E 50.1 28.8 57.5 35q 
CO2H
 
insoluble 
35d 
OH
 
E E 63.1 57.0 90.4 35r 
CO2Me
 
D D 67.4 25.9 38.5 
35e 
OH  
I E 46.5 24.9 53.7 35s 
OH
OC2H5  
D E 51.3 50.3 98.1 
35f 
HO
 
D I 41.3 25.5 61.6 35t 
OH
OC3H7  
D E 28.2 19.3 68.4 
35g 
OH
F  
E E 35.1 27.7 78.8 35u 
OH
OC5H11  
D D 45.1 24.5 54.2 
35h 
OH
Br  
I/E E 37.7 24.2 64.1 35v 
OH
OC8H17  
D D 84.5 21.4 25.3 
35i 
OH
NO2  
E D 76.9 29.5 38.4 35w 
NHAc
 
D D 108.0 36.3 33.6 
35j 
OCH3
OCH3
 
E E 61.7 42.5 69.0 35x 
N
H
N
 
E E 52.7 56.3 106.8 
35k 
OCH3  
I/E E 44.0 30.5 69.3 35y N
H
N
 
E E 67.2 61.7 91.8 
35l 
OMe
 
I I 75.2 35.6 47.3 35z 
H
N
 
I E 93.7 67.8 72.4 
TGN/Golgi phenotypes: D, DMSO-like; I, intermediate; E, Exo2-like. TnfR+ endosome phenotypes: D, DMSO-like; E, Exo2-like.  PS: protein synthesis 
compound only, PST: protein synthesis with toxin challenge. (χ) protective coefficient (%) 5 
. 
N
N
S
HN NH2
N
N
S
NHN Ar
9 35a-z
ArCHO
MeOH
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and the EE (Table 2).  Only the ortho or meta-hydroxyl 
substituted benzyl triazoles 32 and 33 exhibited a modest 
efficacy against SLTx challenge.  We postulate that the more 
flexible benzyl allows presentation of the ortho or meta 
hydroxyl groups in a more favourable orientation to 5 
compensate for the unfavourable positioning of the para 
hydroxy substituent of the more Exo2 like analogues 30, 31 
and 34 by the 1,4-triazole linker. 
Modification of the substituents on ring E 
As no dramatic effects were revealed by modification of the 10 
alkythienopyrimidine core and the hydrazone bond of Exo2, 
these moieties were used as a scaffold for a library of 
hydrazones examining the effect of the substituents on ring E 
and their orientation.  The compounds, their phenotypic 
effects, protein synthesis and compound efficacy (χ) are 15 
shown in Table 3 (Chart 3S in SI) presented in a similar 
manner to the previous analogues.  Generally a para hydroxyl 
substituent confers an Exo2-like phenotype at the EE and 
TGN/Golgi.  Comparatively, meta and ortho hydroxy 
substituents show a reduced Exo2 phenotypic effect (e.g. the 20 
Exo2 isomer 35a and the mono substituted 35e, 35f).  A meta 
methoxy substituent can also elicit an Exo2 phenotypic effect 
(35j, 35k) but with a reduced protective effect against SLTx 
challenge.  Retention of the para OH and substitution of the 
meta methoxy substituent with longer alkyl ethers (35s-35v) 25 
initial gives an improvement with ethoxy analogue 35s 
showing lower toxicity, an excellent efficacy (χ) and 
phenotypic effects focused at the EE.  Further elongation of 
the ether chain quickly loses these benefits to give non-toxic 
inactive compounds (35u, 35v).  A similar loss of activity is 30 
also noted when exchanging the meta methoxy substituent for 
a fluorine (35g), bromine (35h) or to the larger nitro 
substituent (35i).  Interestingly, though having no protective 
effect against SLTx, 35i is able to generate an Exo2-like 
morphological effect at the TGN/Golgi as illustrated by the 35 
redistribution of the cis-Golgi marker GRASP 65,47 and 
confirmed by the dissemination of another cis-Golgi marker 
NA-GFP,48 without eliciting an effect at the EE.  A similar but 
less specific phenotypic effect is demonstrated by fluoro 
analogues 35n and 35o and the pyridine derivative 35p.   40 
 In view of the key para OH, we examined isostere 
replacement with an NH.  This was originally disappointing as 
the acetamide 35w, though of low toxicity exhibited no 
morphological changes or protective effect against SLTx.  
Concerned that the additional bulk of the acetyl group of 35w 45 
was inhibiting receptor binding in a similar manner to the 
increase in size of the meta substituent detailed above, we 
developed the benzimidazole derivative 35x.  This still 
contains the NH but the steric bulk of the meta substituent is 
tied back in the 5-membered ring and the nitrogens of the 50 
benzimidazole 35x are ideally situated to mimic the two 
oxygens of the phenol and methoxy of Exo2.  Pleasingly, 
though benzimidazole derivative 35x showed similar 
morphological effects to Exo2, it exhibited a lower toxicity 
profile and an excellent retention of protein synthesis after 55 
SLTx challenge.  We promptly investigated the related 
indazole and indole analogues 35y and 35z.  Compound 35y 
had reduced toxicity and an excellent protective effect.  
Compound 35z had protein synthesis levels approaching that 
of the control DMSO and retained more than 70% protein 60 
synthesis after SLTx challenge with morphological effects 
target predominantly at the endsosomes. 
 Figure 3 compiles all these toxicity and morphological data 
in a scatter plot of acute challenge with SLTx (protective 
effect) versus inherent compound toxicity, coding split circles 65 
for morphological changes stimulated at the TGN/Golgi (left-
hand side of circles) and TnfR-positive EE (right-hand side of 
circles) as DMSO-like (white), intermediate (gray) or Exo-2 
like (black).  The majority of the compounds fall into three 
main groups:  Cluster 1, predominately Exo2-like, Cluster 2, 70 
containing compounds with mixed features and Cluster 3, 
predominately DMSO-like.  In addition, 35z lies out with 
these clusters, having a good protective effect but being much 
less toxic than the other active Exo2 like compounds 
(Cluster1). 75 
Figure 3. Scatter plot of protective effect against compound toxicity 
Discussion  
We have generated a range of Exo2 derivatives to determine 
structure-activity relationships, with key alterations that 
define Exo2 function and alter specificity.  Here we report 80 
that Exo2 derivatives have differential effects on subcellular 
organelles, and propose that the alkylthienopyrimidine core, 
consisting of rings A, B and C anchors Exo2 in its target 
binding sites, and that the E ring is required for Exo2-like 
activity but also contributes towards innate toxicity.  The 85 
differential effects on organelles imply either that Exo2 has 
multiple targets, or that there is one target that exhibits 
 8  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
varying affinities at the different sites. 
 At the level of light microscopy, none of the compounds 
tested differentiated between the Golgi and TGN, suggesting 
that these structures are linked intimately, with a common (set 
of) Exo2 target(s) which are responsible for maintaining both 5 
of these structures.  We were unable to make any substantially 
dramatic changes to Exo2 at either the E ring, the A, B and C 
moiety or the hydrazone link D connecting them suggesting 
that both ends of the molecule and their relative orientation 
via the hydrazone are critical for engaging with Exo2 targets.  10 
 A para-hydroxyl group on ring E results in dissemination 
of TGN/Golgi structures and swollen endosomes, and strongly 
inhibits the retrograde trafficking pathway of SLTx (e.g. 35b, 
35d and 35g).  The protective effect of this para-hydroxyl 
group is context-dependent and can be eroded by increasing 15 
bulk of substituents at the meta-position highlighted by 
increasing the meta alkoxy chain length from ethoxy to 
octyloxy (35s-v).  Mimicry of the para-hydroxyl group by a 
suitably positioned -NH of a heterocyclic ring (35x-z) 
produces Exo2 analogues with greatly reduced toxicity, more 20 
focused phenotypic effects and superior retention of protein 
synthesis after SLTx challenge, promising features for further 
investigation.  There is no obvious structural relationship 
between Exo2 and BFA (Figure 1).  However, the BFA 
cyclopentane ring carries a hydroxyl group that buries deeply 25 
within the Arf:Arf-GEF BFA-binding cleft, making specific 
contacts with both Arf and Arf-GEF.49  The para-hydroxyl 
group of Exo2 that drives Exo2 activity may therefore make 
similar interactions with a subset of BFA sensitive targets, 
underlining the importance of the hydroxyl group and 30 
suggesting a possible orientation of Exo2 in such clefts.  As 
well as modulating compound toxicity and protective effect, 
the nature of this substituent and its environment (meta 
substituent) also permit the tuning of these interactions with 
different targets.  Clear candidates with differential specificity 35 
are 35s and 35z, which preferentially target the EE and 35i 
which interferes at the Golgi/TGN.     
 The evidence that SLTx normally traffics through the Golgi 
stack is extensive.  There are requirements for the small 
GTPase Arl1,50 the Arl1 effector Golgi tethering factor 40 
golgin-9750, 51 and the Arl1 targeting co-factor ARFRP1.52  In 
addition, the Golgi tethering factors golgin-24553 and 
GCC88,54 the conserved oligomeric Golgi COG complex,55 
the Golgi-associated retrograde protein GARP56 and the TGN 
tethering factor GCC18557 control SLTx trafficking.  45 
Furthermore, roles for the Golgi docking and fusion promoter 
Rab6a58, 59 and its RabGAP Rab6IP260 and for Rab1157, 61 
have been established.  Physically, subcellular microsurgery 
to remove the Golgi stack halts retrograde transport of the 
SLTx B chain to the ER.62  However, we demonstrate here 50 
that a visibly discrete Golgi structure is not an absolutely 
required for SLTx toxicity, since the dispersed Golgi 
fragments stimulated by 35i are either competent for 
retrograde transport or the fused ER-Golgi induced by these 
compounds retains functionality for retrograde transport. 55 
 We conclude that there are at least two Exo2 targets, one 
operating at the TGN/Golgi and the other operational at the 
TnfR+ early endosomes.  Organelle morphology and function 
can be separated by Exo2 derivatives. The 
alkylthienopyrimidine ring anchors Exo2 in the target binding 60 
sites, but the specificity of interaction with Exo2 targets and 
inherent toxicity can be altered by judicious substitution on 
the E ring of Exo2.  Further work is now under way on the 
promising compounds reported here.  The lower toxicity and 
specificity of these derivatives will allow a more rigorous 65 
characterization of cell transport and the opportunity to 
observe recovery pathways. 
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